Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...
Banner Image
Mobile banner image

Pfizer Oncology
Development

Overview - by Phase

Geo Regions

View studies/programs by

Cancer Type Phase
Cancer types
Phases
Study status

Phase 1

Presentation Atirmociclib (PF-07220060)

Atirmociclib (PF-07220060)

CDK4 Inhibitor
Phase 1
Presentation Tegtociclib (PF-07104091) + Atirmociclib (PF-07220060)

Tegtociclib (PF-07104091) + Atirmociclib (PF-07220060)

CDK2 Inhibitor
CDK4 Inhibitor
Phase 1
Presentation Vepdegestrant (ARV-471)* + Atirmociclib (PF-07220060)

Vepdegestrant (ARV-471)* + Atirmociclib (PF-07220060)

PROTAC Estrogen Receptor Degrader
CDK4 Inhibitor
Phase 1
Presentation Bispecific Gamma Delta-T-Cell Engager Directed to EGFR

Bispecific Gamma Delta-T-Cell Engager Directed to EGFR

PF-08046052
Phase 1
Presentation BRAFi

BRAFi

PF-07799933
Phase 1
rotating image for CD228-directed Antibody-Anticalin® Bispecific Protein

CD228 and 4-1BB-directed Antibody-Anticalin® Bispecific Protein

PF-08046049
Phase 1
Presentation CD228V directed Antibody Drug Conjugate

CD228V directed Antibody Drug Conjugate

PF-08046031 | CD228V
Phase 1
Presentation CD25V Directed Antibody Drug Conjugate

CD25V Directed Antibody Drug Conjugate

PF-08046032
Phase 1
Presentation CD30-directed Antibody-Glucuronide with TOP1 Inhibitor Payload

CD30-directed Antibody-Glucuronide with TOP1 Inhibitor Payload

PF-08046044
Phase 1
rotating gif of SGN-35T

CD30-directed Antibody-Tripeptide MMAE Conjugate

PF-08046045
Phase 1
Presentation CEACAM5-directed Antibody Drug Conjugate

CEACAM5-directed Antibody Drug Conjugate

PF-08046050
Phase 1
rotating image for Disitamab vedotin

Disitamab vedotin (PF-08046051)

HER2-directed Antibody Drug Conjugate
Phase 1
image representing elranatamab

Elranatamab

BCMA-CD3 Bispecific Antibody
Phase 1
image representing elranatamab

Elranatamab + Maplirpacept (TTI-622 | PF-07901801)

BCMA-CD3 Bispecific Antibody
SIRPα-IgG4 Fusion Protein
Phase 1
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Phase 1
Presentation KAT6 Inhibitor

KAT6 Inhibitor

PF-07248144
Phase 1
Presentation KRAS Inhibitor

KRAS Inhibitor

PF-07934040
Phase 1
Presentation KRAS Inhibitor

KRAS Inhibitor

PF-07985045
Phase 1
Presentation LILRB1/2 Bispecific IgG1 Antibody

LILRB1/2 Bispecific IgG1 Antibody

PF-07826390
Phase 1
image representing maplirpacept

Maplirpacept (TTI-622 | PF-07901801)

SIRPα-IgG4 Fusion Protein
Phase 1
Presentation MEK Brain Penetrant Inhibitor

MEK Brain Penetrant Inhibitor

PF-07799544 
Phase 1
Presentation Mesothelin-Targeted Antibody Drug Conjugate

Mesothelin-Targeted Antibody Drug Conjugate

PF-08052666
Phase 1
Presentation Mevrometostat (PF-06821497)

Mevrometostat (PF-06821497)

EZH2 Inhibitor
Phase 1
rotating gif for Non-Fucosylated CD70-directed Antibody

Non-Fucosylated CD70-directed Antibody

PF-08046040 
Phase 1
rotating gif of PF-08046054, SGN-PDL1V

PD-L1-directed Antibody Drug Conjugate

PF-08046054
Phase 1
Presentation PDL1iT: Immunostimulatory Drug Conjugate (ISAC) targeted to PD-L1 with a TLR7 agonist payload

PDL1iT: Immunostimulatory Drug Conjugate (ISAC) targeted to PD-L1 with a TLR7 agonist payload

PF-08046037
Phase 1
Presentation Ponsegromab (PF-06946860)

Ponsegromab (PF-06946860)

GDF-15 Monoclonal Antibody

Ponsegromab | PF-06946860 
Phase 1
green molecule rotates

Sigvotatug vedotin

Integrin beta-6 directed Antibody Drug Conjugate
Phase 1
rotating image of Tisotumab vedotin

Tisotumab vedotin

TF-directed Antibody Drug Conjugate
Phase 1
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Phase 1
Presentation Vepdegestrant (ARV-471)*

Vepdegestrant (ARV-471)*

PROTAC Estrogen Receptor Degrader
Phase 1

Phase 2

Presentation Vepdegestrant (ARV-471)* + Atirmociclib (PF-07220060)

Vepdegestrant (ARV-471)* + Atirmociclib (PF-07220060)

PROTAC Estrogen Receptor Degrader
CDK4 Inhibitor
Phase 2
Presentation Tegtociclib (PF-07104091) + Atirmociclib (PF-07220060)

Tegtociclib (PF-07104091) + Atirmociclib (PF-07220060)

CDK2 Inhibitor
CDK4 Inhibitor
Phase 2
Presentation Atirmociclib (PF-07220060)

Atirmociclib (PF-07220060)

CDK4 Inhibitor
Phase 2
Presentation Encorafenib + Binimetinib

Encorafenib + Binimetinib

BRAF Inhibitor
MEK Inhibitor
Phase 2
rotating image for Brentuximab vedotin

Brentuximab vedotin

CD30-directed Antibody Drug Conjugate
Phase 2
rotating image for Disitamab vedotin

Disitamab vedotin (PF-08046051)

HER2-directed Antibody Drug Conjugate
Phase 2
image representing elranatamab

Elranatamab

BCMA-CD3 Bispecific Antibody
Phase 2
Presentation Encorafenib

Encorafenib

BRAF Inhibitor
Phase 2
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Phase 2
image representing maplirpacept

Maplirpacept (TTI-622 | PF-07901801)

SIRPα-IgG4 Fusion Protein
Phase 2
Image representing palbociclib

Palbociclib

CDK4/6 Inhibitor
Phase 2
Presentation Sasanlimab

Sasanlimab

Anti-PD-1 Monoclonal Antibody (mAb)
Phase 2
Presentation Tegtociclib (PF-07104091)

Tegtociclib (PF-07104091)

CDK2 Inhibitor
Phase 2
rotating image of Tisotumab vedotin

Tisotumab vedotin

TF-directed Antibody Drug Conjugate
Phase 2
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Phase 2
Presentation Vepdegestrant (ARV-471)*

Vepdegestrant (ARV-471)*

PROTAC Estrogen Receptor Degrader
Phase 2

Phase 3

Presentation Atirmociclib (PF-07220060)

Atirmociclib (PF-07220060)

CDK4 Inhibitor
Phase 3
Presentation Encorafenib + Binimetinib

Encorafenib + Binimetinib

BRAF Inhibitor
MEK Inhibitor
Phase 3
rotating image for Brentuximab vedotin

Brentuximab vedotin

CD30-directed Antibody Drug Conjugate
Phase 3
rotating image for Disitamab vedotin

Disitamab vedotin (PF-08046051)

HER2-directed Antibody Drug Conjugate
Phase 3
image representing elranatamab

Elranatamab

BCMA-CD3 Bispecific Antibody
Phase 3
Presentation Encorafenib

Encorafenib

BRAF Inhibitor
Phase 3
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Phase 3
Presentation Mevrometostat (PF-06821497)

Mevrometostat (PF-06821497)

EZH2 Inhibitor
Phase 3
Image representing palbociclib

Palbociclib

CDK4/6 Inhibitor
Phase 3
Presentation Vepdegestrant (ARV-471)* + Palbociclib

Vepdegestrant (ARV-471)* + Palbociclib

PROTAC Estrogen Receptor Degrader
CDK4/6 Inhibitor
Phase 3
Presentation Sasanlimab

Sasanlimab

Anti-PD-1 Monoclonal Antibody (mAb)
Phase 3
green molecule rotates

Sigvotatug vedotin

Integrin beta-6 directed Antibody Drug Conjugate
Phase 3
Presentation Talazoparib

Talazoparib

PARP Inhibitor
Phase 3
rotating image of Tisotumab vedotin

Tisotumab vedotin

TF-directed Antibody Drug Conjugate
Phase 3
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Phase 3
Presentation Vepdegestrant (ARV-471)*

Vepdegestrant (ARV-471)*

PROTAC Estrogen Receptor Degrader
Phase 3

Efficacy and safety of these products, for the uses identified within, are currently under investigation. Regulatory approval of any of these products or uses is dependent on the completion of the study programs and review by regulatory authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of August 5, 2025.

*Vepdegestrant is being co-developed with Arvinas.

Anticalin® is a registered US trademark of Pieris Pharmaceuticals Gmbh.